Exosomal lncRNA HOTTIP Mediates Antiviral Effect of Tenofovir Alafenamide (TAF) on HBV Infection
Qing-Min Liu,1,* Yi-Yu He,2,* Li-Li Liu,3 Li-Kun Wang4 1Intensive Care Unit, Linyi People’s Hospital, Linyi, Shandong Province, People’s Republic of China; 2Department of Cardiovascular Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, People’s Republic of China; 3...
Guardado en:
Autores principales: | Liu QM, He YY, Liu LL, Wang LK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fd79de68b1cf45d1824f91eb6955989e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
por: Pei-Yuan Su, et al.
Publicado: (2021) -
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
por: Sara Jeong, et al.
Publicado: (2021) -
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
por: Calvin Q Pan, et al.
Publicado: (2021) -
Tenofovir induced lichenoid drug eruption
por: Mrinal Gupta, et al.
Publicado: (2015) -
APPLICATION OF HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHIC METHOD FOR THE SIMULTANEOUS DETERMINATION OF LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE IN PHARMACEUTICAL DOSAGE FORM
por: CHANDRA,P, et al.
Publicado: (2011)